Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
221
resultados
Última actualización
24/10/2026 [07:05:00]
Resultados 125 a 150 de 221
Resumen de: US20260315406A1
There is provided a compound represented by general formula (1) for preparing lipid nanoparticles encapsulating a therapeutic, prophylactic and/or biological agent: wherein A comprises a hydrophilic moiety selected from carbohydrate/sugar/saccharide and derivatives thereof; X1 is —ORa or —NRbRc; X4 is —ORy, —SRz or a hydrophilic group, where Ry to Rz are independently selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; X2 and X3 are each independently —O— or —NR6—, where Ra to Rd are independently selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; R1 and R2 are each independently a hydrophobic group; R3, R4, R5, R6 and R10 are each independently H, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; R7, R9, R11 and R12 are each independently optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; R13 is H, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl, or —C(═O)R14, where R14 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl; w≥1; x is 0 or ≥1; y is 0 or ≥1; and z is 0 or ≥1.
Resumen de: US20260315391A1
0000 In various aspects and embodiments provided are compositions containing extracellular vesicles (including modified extracellular vesicles), methods of making preparations of extracellular vesicles, methods of modifying extracellular vesicles and methods of using modified and/or unmodified extracellular vesicles.
Resumen de: US20260315389A1
This disclosure relates to delivery vehicles comprising payload molecules, e.g., mRNA for the treatment of cystic fibrosis (CF). Nucleic acid therapeutics (e.g., mRNAs) when administered in vivo encode cystic fibrosis transmembrane conductance regulator (CFTR). Nucleic acid therapeutics (e.g., mRNAs) of the disclosure increase and/or restore deficient levels of CFTR expression and/or activity in subjects.
Resumen de: KR20260150364A
0001a 광 반응성 나노 플랫폼이 개시되어 있다. 이 개시된 광 반응성 나노 플랫폼은 하이드록시아파타이트 나노입자; 하이드록시아파타이트 나노입자에 도핑된 금속 이온; 및 하이드록시아파타이트 나노입자 표면에 결합된 표적화 리간드 및 광감응제를 포함한다.
Resumen de: WO2026215538A1
The present invention refers to the medical field. Particularly, it refers to a chitosan-based nanocapsule system for use in the prophylactic treatment of an infection caused by a respiratory pathogen, preferably an enveloped respiratory virus, wherein the nanocapsule system is administered intranasally.
Resumen de: WO2026217888A1
Compositions including a nucleotide sequence as set forth in SEQ ID NO: 1 and/or having 95% homology to SEQ ID NO:1, more preferably having 99% homology to SEQ ID NO: 1 wherein each uracil loci in SEQ ID NO: 1 has been substituted with 5-Methoxyuridine (5 MOU) and/or N1-Methylpseudouridine (N1). A method of treating and/or preventing human erectile dysfunction in a subject in need thereof by (a) contacting human penile cells with a composition having a nucleotide sequence as set forth in SEQ ID NO: 1 and/or having 95% homology to SEQ ID NO:1, more preferably having 99% homology to SEQ ID NO: 1 wherein each uracil loci in SEQ ID NO: 1 has been substituted with 5-Methoxyuridine (5 MOU) and/or N1-Methylpseudouridine (N1 ).
Resumen de: WO2026213647A1
Described herein are functionalised particles, comprising particle shells comprising a plurality of projections extending outwardly therefrom, wherein the functionalised particles comprise one or more metal complexes adsorbed thereon and one or more basic functional groups and wherein the functionalised particles are at least partially coated with a biological molecule, as well as methods relating to same, and uses thereof.
Resumen de: WO2026216848A1
The present invention relates to targeting ligand-expressing enveloped virus-like particles (VLPs) and, specifically, to targeting ligand-expressing enveloped VLPs wherein a targeting ligand is fused to an envelope protein among proteins constituting the VLPs, the targeting ligand is expressed on the surface of the VLPs and is located at an ectodomain on the N-terminal side of the envelope protein, and a carrier is included inside the VLPs. In particular, when loaded with a photosensitizer such as KillerRed, the VLPs can significantly improve photodynamic therapy (PDT) efficiency through the generation of target cell-specific reactive oxygen species (ROS) and simultaneously induce immunogenic cell death (ICD) accompanied by calreticulin exposure and ATP release, and thus can be effectively used for tumor-targeted therapy and antitumor immunotherapy.
Resumen de: WO2026217959A1
The present disclosure provides, for instance, methods and compositions for targeting one or more SRC family kinases. In some embodiments, the composition is an RNA duplex. In some embodiments, the RNA duplex is comprised in a lipid nanoparticle. The present disclosure also provides, for instance, methods and compositions for treating cancer, e.g., breast cancer or ovarian cancer. In some embodiments, the cancer is resistant or refractory to a taxane drug.
Resumen de: WO2025172861A2
This invention relates to compositions including acid addition salt formulations including a compound of formula (I). Also disclosed are methods of their use and preparation.
Resumen de: US20260315621A1
0000 A nano-size controllable and stable polymer-drug conjugate, an intermediate thereof, and a use thereof. Provided is a polymer-drug conjugate as represented by formula (I) and having different polymer bodies, a controllable coupled group quantity, controllable group coupling sites and a controllable nano-size. The drug conjugate has one or more of the following advantages: a low renal clearance rate, a low liver-spleen clearance rate, long plasma half-life, strong drug accumulation capability at lesion tissues, strong drug permeability at lesion tissues, low toxic and side effects, and an excellent treatment effect.
0000
Resumen de: US20260317349A1
0000 The present invention relates to a macrocyclic chelating agent capable of site-specific modification, a nuclide probe, and a use thereof, and in particular to a compound as represented by formula I, or a precursor compound, isotope compound, salt, or hydrate thereof. Compared with common macrocyclic chelating agents, the macrocyclic chelating agent of the present application can be used for site-specific modification of various target molecules at R<4 >site, comprising antibodies, polypeptides, sugars, nucleic acids, small molecule drugs, optical dyes, organic nanomaterials or fragments or derivatives thereof, and the reaction is more accurate and efficient. The macrocyclic chelating agent can be chelated with radionuclides for imaging such as PET, SPECT, MRI, etc., or for research on the application of radionuclide therapy.
0000
Resumen de: US20260315401A1
0000 Provided herein is a method for delivering an RNA composition to a subject for in vivo production of a protein or a peptide in the subject, comprising administering to the subject an RNA composition comprising a polynucleotide that encodes a protein or a peptide, formulated within (a) a plurality of lipid nanoparticles (LNP) comprising synthetic structural lipids and an ionizable lipid, or (b) a lipid reconstructed natural messenger packs (LNMPs) comprising natural lipids and an ionizable lipid. Also provided herein are methods for treating diseases or disorders associated with the gastrointestinal tract, stomach, small or large intestine, mesenteric lymph node, pancreas, colon or rectum, caecum, and/or spleen, comprising orally or enterally administering the RNA composition described herein.
Resumen de: WO2026216916A1
The present invention relates to a composition for treating severe fever with thrombocytopenia syndrome, the composition comprising mRNA of a human monoclonal antibody against SFTSV. The composition according to the present invention increases the survival rate of SFTSV-infected mice and helps in quickly recovering from organ failure, and thus can be used for SFTSV treatment.
Resumen de: WO2026215779A1
The present invention relates to plant vesicles obtained from Eruca Sativa, food supplements comprising them and their uses in maintaining intestinal well-being, in restoring the diversity of the intestinal microbiota in a subject affected by intestinal dysbiosis, in the prevention and/or treatment of obesity, cerebral senescence and the overall decline in neurocognitive functions caused by neuroinflammation.
Resumen de: WO2026217909A1
Provided herein are compositions and methods for generating mucosal immunity against a pathogen or cancer cell. In particular, provided herein are circular RNA based vaccines formulated for pulmonary delivery and the use of such vaccines to generate mucosal immunity for disease prophylaxis and therapy (e.g., against respiratory viruses and lung-residing cancers).
Resumen de: WO2026217958A1
The present disclosure provides, for instance, methods and compositions for targeting one or more of CDK4, CDK6, and HIF1A. The present disclosure also provides, for instance, methods and compositions for treating cancer, e.g., breast cancer, colorectal cancer, or brain cancer, using a lipid nanoparticle composition described herein. In some embodiments, the lipid nanoparticle is directly injected into a solid tumor.
Resumen de: KR20260150583A
본 발명은 표적 리간드 발현 외피형 바이러스 유사입자에 관한 것으로서, 구체적으로 바이러스 유사입자(Virus-Like Particle, VLP)를 구성하는 단백질 중 외피 단백질에 표적리간드가 융합되고, 상기 표적 리간드는 상기 바이러스 유사입자의 표면에 발현되고 상기 외피 단백질의 N-말단 측 세포 외부 돌출부위(ectodomain)에 위치하며, 상기 바이러스 유사입자의 내부에는 담지체가 포함되는 것을 특징으로 하는, 표적 리간드 발현 외피형 바이러스 유사입자에 관한 것이다. 특히 내부에 킬러레드(KillerRed) 등의 광감작제를 탑재할 경우, 표적 세포 특이적인 활성 산소(ROS) 생성을 통한 광역학 치료(PDT) 효율을 유의미하게 향상시킬 수 있으며, 동시에 칼레티쿨린 노출 및 ATP 방출을 동반하는 면역원성 세포 사멸(ICD)을 유도할 수 있어 종양 표적 치료 및 항종양 면역 치료에 유용하게 활용될 수 있다.
Resumen de: WO2026214581A1
The present invention provides an anti-protein-adhesion cell-affinity zwitterionic polymer. The zwitterionic polymer is used as a drug delivery carrier. By regulating the hydrophilicity and hydrophobicity of a substituent of a zwitterionic unit, the zwitterionic polymer exhibits an anti-protein-adhesion property in blood circulation, and meanwhile, at a tumor site, adsorbs to a cell membrane to trigger rapid transcytosis, thereby achieving efficient tumor vascular extravasation and intratumoral penetration. The present invention solves the problem of low cellular uptake caused by a strong hydration effect of conventional zwitterionic carriers, and is suitable for targeted delivery of chemotherapeutic drugs, nucleic acids, protein drugs, and the like.
Resumen de: WO2026214438A1
The present application relates to a nanocarrier based on self-assembly of a protein and a hydrophobic polymer, a nano drug delivery system, a preparation method for the nanocarrier, and a use of the nanocarrier. The nanocarrier is nanoparticles formed by self-assembly of an amphiphilic protein and a hydrophobic polymer driven by hydrophobic interactions, wherein the hydrophobic polymer is encapsulated inside the nanoparticles by the amphiphilic protein. The nanocarrier has the advantages of high drug loading capacity, high encapsulation efficiency, high colloidal stability, good uniformity and production reproducibility, good dispersibility, good biocompatibility, a simple formulation, low energy consumption and the like. The nanocarrier can be used for drug delivery and can also be used for contrast-enhanced imaging of tumor sites. Moreover, drug molecules can be loaded at different positions of the nanocarrier on the basis of different requirements, and the nanocarrier has diverse structures and compositions, and can satisfy the requirements of different application scenarios.
Resumen de: WO2026214648A1
The present invention provides a lipid compound comprising a cyclic urea structure, and specifically relates to a compound of formula (I), or an isotopic variant, tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present invention also provides a nanoparticle pharmaceutical composition comprising the compound, and a use of the compound and the composition comprising the compound in muscle-specific delivery of nucleic acids.
Resumen de: US20260315404A1
0000 A prophylactic vaccine composition that is intended for mammals and birds comprises a killed whole bacterium, the bacterium being covered with a cationic agent, in particular, cationic nanoparticles.
Resumen de: US20260317336A1
0000 An ionizable lipid, and a drug delivery system containing the ionizable lipid are provided. Specifically, the ionizable lipid may have the structure of formula (I). A pharmaceutically acceptable salt, tautomer, or stereoisomer of the ionizable lipid is also provided. A lipid nanoparticle constructed by means of using the ionizable lipid can realize safe and efficient delivery of nucleic acid drugs, small-molecule drugs, peptide drugs and protein drugs.
0000
Resumen de: US20260315596A1
The present invention discloses a hybrid metal-lipid nanoparticle for targeted therapy comprising properties of organic and inorganic nanoparticles (NPs), combined in a single formulation to obtain NPs with unique attributes. This will allow the synergistic effect between drug delivery (also known as chemotherapy) and photothermal therapy. This strategy relies on the construction of hybrid metallic-gold nanoparticles using a dual functionality by lipid nanoparticles (as organic components and drug delivery system) in the core and gold nanorods (as inorganic component and a heat delivery system) in the shell, linked by a tumor-targeting peptide. The active targeting strategy was implemented to guarantee a specific delivery to the brain by using transferrin (targeting the blood-brain barrier) and cRGDfK (not only used to target GB tumor barrier but also as a linker between both inorganic and organic nanoparticles).
Nº publicación: US20260315624A1 15/10/2026
Solicitante:
IMUNON INC [US]
IMUNON, INC.
Resumen de: US20260315624A1
0000 The present disclosure relates to a combination therapy comprising an immune checkpoint inhibitor, a nanoparticle formulated plasmid comprising an IL-12 coding nucleic acid, and, optionally, at least one adjunctive chemotherapeutic drug, and methods of treatment using such combination therapies and/or compositions.
BOPI
Sede Electrónica
